Provided by Tiger Trade Technology Pte. Ltd.

Organon & Co

6.23
-0.1600-2.50%
Post-market: 6.240.0100+0.16%19:01 EDT
Volume:3.32M
Turnover:20.63M
Market Cap:1.62B
PE:8.65
High:6.29
Open:6.26
Low:6.16
Close:6.39
52wk High:15.88
52wk Low:6.16
Shares:259.98M
Float Shares:258.73M
Volume Ratio:1.06
T/O Rate:1.28%
Dividend:0.08
Dividend Rate:1.28%
EPS(TTM):0.7200
EPS(LYR):0.7200
ROE:30.56%
ROA:6.22%
PB:2.15
PE(LYR):8.65

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-PepGen, Turbo Energy, Qualcomm

Reuters
·
Oct 28, 2025

Piper Sandler Downgrades Organon to Underweight From Overweight, $5 Price Target

MT Newswires Live
·
Oct 28, 2025

Organon downgraded to Underweight from Overweight at Piper Sandler

TIPRANKS
·
Oct 27, 2025

Organon & Co : Piper Sandler Cuts to Underweight From Overweight; Cuts Target Price to $5 From $18

THOMSON REUTERS
·
Oct 27, 2025

Organon falls -21.0%

TIPRANKS
·
Oct 27, 2025

Organon Shares Hit Record Low as CEO Kevin Ali Resigns After Probe Into Birth Control Implant Sales, Last Down 21%

THOMSON REUTERS
·
Oct 27, 2025

BRIEF-Organon Appoints Company Executive Joseph Morrissey As Interim CEO And Board Chair Carrie Cox As Executive Chair Announces Results Of Audit Committee Investigation

Reuters
·
Oct 27, 2025

Organon Appoints Joseph Morrissey as Interim CEO After Investigation Finds Possible Sales Practice Irregularities

MT Newswires Live
·
Oct 27, 2025

Organon Shares Down 17.5% Premarket as CEO Kevin Ali Resigns After Probe Into Birth Control Implant Sales

THOMSON REUTERS
·
Oct 27, 2025

Organon & Co: Initiating a Search for a Permanent CEO, Including Both Internal and External Candidates

THOMSON REUTERS
·
Oct 27, 2025

Organon & Co - Kevin Ali Resigns as CEO and Board Member

THOMSON REUTERS
·
Oct 27, 2025

Organon & Co: Findings to Date Do Not Necessitate a Restatement or Revision to Any Previously Issued Financial Statements

THOMSON REUTERS
·
Oct 27, 2025

Organon & Co: in Connection With Investigation, Terminated Employment of Head of U.S. Commercial & Government Affairs

THOMSON REUTERS
·
Oct 27, 2025

Organon & Co: Taking Remedial Actions to Improve Its Financial Controls and Address Any Material Weaknesses

THOMSON REUTERS
·
Oct 27, 2025

Organon: Investigation Found That Some Wholesalers in US Were Asked to Buy More Nexplanon Than Needed at End of Q4 2022, Q3 & Q4 2024, Q1, Q2, Q3 2025

THOMSON REUTERS
·
Oct 27, 2025

Organon: Investigation Found Nexplanon Sales Represented Less Than 1% of Co's Consolidated Revenue for Year Ended Dec 31, 2022 or Dec 31, 2024

THOMSON REUTERS
·
Oct 27, 2025

Organon & Co: Improper Nexplanon Sales Practices Enabled Co to Meet Guidance and/or Certain External Revenue Expectations

THOMSON REUTERS
·
Oct 27, 2025

Organon & Co: There Has Been No Finding That CFO Was Aware of Improper Wholesaler Sales Practices

THOMSON REUTERS
·
Oct 27, 2025

Organon & Co - Appoints Joseph Morrissey as Interim CEO

THOMSON REUTERS
·
Oct 27, 2025

Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation

THOMSON REUTERS
·
Oct 27, 2025